BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

FDA Grants Priority Review for Cefepime-Taniborbactam to Treat cUTI

Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's N...

August 16, 2023 | News

Kelun-Biotech's Phase III Trial of SKB264 Meets Endpoint in Advanced TNBC

Kelun-Biotech recently held an Independent Data Monitoring Committee (IDMC) meeting to review the interim analysis data of the Phase III clinical trial of ...

August 15, 2023 | News

TB Alliance and Remington Pharma Partner to Launch New Therapy for Drug-Resistant TB in Pakistan

Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tubercul...

August 15, 2023 | News

CAS and Molecule.one Partner to Speed Up Drug Discovery

CAS, a division of the American Chemical Society specializing in scientific information solutions, and Molecule.one, a tech-bio leader in AI-based solution...

August 14, 2023 | News

First Patient Dosed in Phase III Prostate Cancer Imaging Study of TLX591-CDx in China

The Phase III Illuccix China study (ClinicalTrials.gov ID: NCT05847348) is a prospective, open-label, single-arm, multicenter study in Chinese...

August 11, 2023 | News

Standigm and Nashville Biosciences join to revolutionize early drug discovery

Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced that it is collaborating with N...

August 11, 2023 | News

Pharming Enrolls First Patient in Japanese APDS Treatment Trial

Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase ...

August 10, 2023 | News

GenScript Expands Peptide Production Capabilities to Include Neoantigen Peptides and APIs

GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has ramped up production of complex and modi...

August 09, 2023 | News

First Patient Dosed in TLX101 Brain Cancer Study for Newly Diagnosed Glioblastoma

IPAX-2 (ClinicalTrials.gov Identifier: NCT05450744) is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with externa...

August 08, 2023 | News

Ascentage Pharma Gets FDA Clearance for Global Phase III Trial of Lisaftoclax in CLL/SLL Patients

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related...

August 07, 2023 | News

US FDA Grants Orphan Drug Status to ABM-1310 for BRAF V600 Glioblastoma

Orphan Drug Designation is a significant recognition bestowed by the FDA to the drugs used in the treatment of rare diseases. This designation intends to e...

August 03, 2023 | News

Doer Biologics Initiates Phase I MAD Trial of DR10624, Receives NMPA IND Approval

The Phase I MAD study is a randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics ...

August 02, 2023 | News

NMPA and FDA Approve First-in-Human Trial for LBL-034 in Multiple Myeloma

This is a first-in-human, single-arm, multicenter, open-label, dose-escalation and expansion clinical study, and plans to enroll patients with relapsed/ref...

August 01, 2023 | News

Everest Medicines Completes Patient Enrollment for Nefecon® China Study

The cOLE study offers an additional 9 months of treatment with Nefecon® to all qualifying patients who have completed the NefIgArd study and will evalu...

August 01, 2023 | News

Stay Connected